Artelo Biosciences (ARTL) Competitors $9.00 -0.03 (-0.33%) Closing price 04:00 PM EasternExtended Trading$9.15 +0.15 (+1.67%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARTL vs. SONN, RLYB, NAII, TAOX, NNVC, CING, PASG, QTTB, BCAB, and IXHLShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Sonnet BioTherapeutics (SONN), Rallybio (RLYB), Natural Alternatives International (NAII), Synaptogenix (TAOX), NanoViricides (NNVC), Cingulate (CING), Passage Bio (PASG), Q32 Bio (QTTB), BioAtla (BCAB), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Its Competitors Sonnet BioTherapeutics Rallybio Natural Alternatives International Synaptogenix NanoViricides Cingulate Passage Bio Q32 Bio BioAtla Incannex Healthcare Sonnet BioTherapeutics (NASDAQ:SONN) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Do insiders and institutionals have more ownership in SONN or ARTL? 9.5% of Sonnet BioTherapeutics shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by company insiders. Comparatively, 5.8% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer SONN or ARTL? Sonnet BioTherapeutics currently has a consensus price target of $20.00, indicating a potential upside of 463.38%. Artelo Biosciences has a consensus price target of $24.00, indicating a potential upside of 166.67%. Given Sonnet BioTherapeutics' higher possible upside, research analysts plainly believe Sonnet BioTherapeutics is more favorable than Artelo Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Artelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.60 Which has more risk and volatility, SONN or ARTL? Sonnet BioTherapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Which has preferable earnings and valuation, SONN or ARTL? Sonnet BioTherapeutics has higher revenue and earnings than Artelo Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonnet BioTherapeutics$20K1,198.13-$7.44MN/AN/AArtelo BiosciencesN/AN/A-$9.83M-$19.05-0.47 Is SONN or ARTL more profitable? Artelo Biosciences' return on equity of -497.68% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sonnet BioTherapeuticsN/A -4,646.10% -342.21% Artelo Biosciences N/A -497.68%-213.76% Does the media refer more to SONN or ARTL? In the previous week, Artelo Biosciences had 3 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 5 mentions for Artelo Biosciences and 2 mentions for Sonnet BioTherapeutics. Sonnet BioTherapeutics' average media sentiment score of 0.90 beat Artelo Biosciences' score of 0.74 indicating that Sonnet BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonnet BioTherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artelo Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryArtelo Biosciences beats Sonnet BioTherapeutics on 8 of the 13 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.30M$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E Ratio-0.4721.2230.8326.39Price / SalesN/A206.90382.9086.63Price / CashN/A44.2437.7259.11Price / Book-4.508.0710.106.62Net Income-$9.83M-$54.08M$3.26B$265.42M7 Day Performance-6.05%3.94%3.90%3.58%1 Month Performance-34.45%3.02%3.73%0.46%1 Year Performance16.29%6.84%37.68%19.41% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences3.0957 of 5 stars$9.00-0.3%$24.00+166.7%+17.6%$6.30MN/A-0.475Analyst ForecastSONNSonnet BioTherapeutics3.239 of 5 stars$3.65+1.5%$20.00+448.7%-41.4%$24.62M$1M0.0010Gap UpRLYBRallybio3.008 of 5 stars$0.58-1.0%$5.00+768.1%-47.7%$24.07M$640K-0.6140NAIINatural Alternatives International1.4615 of 5 stars$3.87-2.8%N/A-32.8%$23.92M$113.80M-2.78290Positive NewsHigh Trading VolumeTAOXSynaptogenixN/A$6.83-2.6%N/AN/A$23.84MN/A-0.344Positive NewsNNVCNanoViricides0.2625 of 5 stars$1.46-1.4%N/A-28.5%$23.47MN/A-2.0320News CoverageGap UpCINGCingulate2.365 of 5 stars$4.30+2.1%$26.25+510.6%-58.1%$23.26MN/A-1.0520Analyst RevisionPASGPassage Bio4.0107 of 5 stars$7.21-3.7%$91.75+1,173.4%-57.1%$22.91MN/A-0.40130Positive NewsGap UpQTTBQ32 Bio2.8014 of 5 stars$1.87-4.9%$12.17+549.2%-95.3%$22.86MN/A-0.4439Positive NewsBCABBioAtla2.5907 of 5 stars$0.38+7.9%$5.00+1,202.1%-78.3%$22.55M$11M-0.3560IXHLIncannex Healthcare0.2304 of 5 stars$0.76+2.5%N/A-63.0%$22.28M$10K-0.633News CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies Sonnet BioTherapeutics Alternatives Rallybio Alternatives Natural Alternatives International Alternatives Synaptogenix Alternatives NanoViricides Alternatives Cingulate Alternatives Passage Bio Alternatives Q32 Bio Alternatives BioAtla Alternatives Incannex Healthcare Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTL) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access